Genflow Biosciences Advances Patent Protection for Longevity Gene Therapy Platform
Key Insights
Genflow Biosciences (search) achieved a major intellectual property milestone with the European Patent Office (search)'s official publication of patent EP4630038 for its longevity gene therapy (search) platform.
The patent application has entered its final pre-grant phase under article 67(3) EPC, representing formal recognition of the patentability of key claims by the European Patent Office (search).
CEO Eric Leire emphasized that securing European patent recognition strengthens the company's strategic position for future partnerships and funding opportunities.
Genflow Biosciences (search) PLC reported significant progress in securing intellectual property protection for its longevity gene therapy (search) platform, with the European Patent Office (search) officially publishing one of the company's European patents last Wednesday. The London-based biotechnology firm described the development as a "major milestone" in its intellectual property strategy.
Patent Publication Milestone
The European Patent Office (search) has recognized the patentability of claims in Genflow's Euro-PCT application, with patent publication number EP4630038 appearing in the EPO bulletin. According to the company, this publication signifies that the patent application has entered its final pre-grant phase under article 67(3) EPC.
"This publication represents a major step toward securing European patent recognition for key elements of Genflow's longevity gene therapy (search) platform," the company stated. However, Genflow noted that additional steps remain before the patent receives formal grant status.
Strategic Implications
Chief Executive Eric Leire emphasized the broader significance of this intellectual property development for the company's future prospects. "The publication by the EPO represents a major validation of our scientific innovation and long-term IP strategy," Leire said. "Securing formal European recognition for our patent moves us closer to full protection of our longevity gene therapy (search) platform and strengthens our strategic position for future partnerships and funding opportunities."
Market Response
The patent publication announcement generated positive investor response, with Genflow Biosciences (search) shares rising 6.8% to 2.40 pence on Monday afternoon trading in London. This market reaction reflects investor confidence in the company's intellectual property strategy and the potential commercial value of its longevity gene therapy (search) platform.
The patent protection progress represents a crucial step for Genflow as it works toward full protection of its therapeutic platform, positioning the company for potential strategic partnerships and additional funding rounds in the competitive gene therapy sector.